[Prognostic factors and risk of recurrence in a series of 385 patients with superficial bladder carcinoma treated with thiotepa, adriamycin or cisplatin].
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002945:Cisplatin / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology*; D011379:Prognosis; D012044:Regression Analysis; D012306:Risk; D013852:Thiotepa / Q000627:therapeutic use; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000601:surgery
D000970:Antineoplastic Agents; D004317:Doxorubicin; D013852:Thiotepa; D002945:Cisplatin
Factores pronósticos y de riesgo de recidiva en una serie de 385 pacientes con carcinoma vesical superficial tratados con tiotepa, adriamicina o cisplatino.